secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2025-05-29T23:59:59+00:00
Accession:  0001140361-25-020713
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant Q4 net loss widens to $206.5M; brepocitinib DM readout on track for H2 2025
--------------------------------------------------------------------------------

- Net loss attributable to Roivant of $206.5M ($0.29 loss per share) for Q4 FY2025, vs $151.1M loss ($0.19) a year ago.
- Revenue of $7.6M, down 16% YoY; R&D expenses rose 35% to $145.2M.
- Consolidated cash, equivalents, restricted cash and marketable securities of $4.9B at March 31, 2025.
- Repurchased $1.3B of shares, reducing outstanding shares by 14% from March 31, 2024.
- Brepocitinib Phase 3 in dermatomyositis fully enrolled; topline data expected H2 2025; NIU Phase 3 enrolling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036125020713/0001140361-25-020713-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036125020713/ef20049462_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-020713

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer